TransMedics [TMDX] vs Bio-Rad Laboratories [BIO] Detailed Stock Comparison

TransMedics

NASDAQ
Loading...

Bio-Rad Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: TransMedics wins in 6 metrics, Bio-Rad Laboratories wins in 13 metrics, with 0 ties. Bio-Rad Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricTransMedicsBio-Rad LaboratoriesBetter
P/E Ratio (TTM)58.4327.55Bio-Rad Laboratories
Price-to-Book Ratio12.381.16Bio-Rad Laboratories
Debt-to-Equity Ratio163.1019.73Bio-Rad Laboratories
PEG Ratio0.33-0.24Bio-Rad Laboratories
EV/EBITDA40.5020.23Bio-Rad Laboratories
Profit Margin (TTM)13.49%12.50%TransMedics
Operating Margin (TTM)23.24%12.19%TransMedics
EBITDA Margin (TTM)23.24%12.19%TransMedics
Return on Equity28.21%4.59%TransMedics
Return on Assets (TTM)5.80%1.59%TransMedics
Free Cash Flow (TTM)$-80.94M$266.20MBio-Rad Laboratories
1-Year Return-15.73%-8.24%Bio-Rad Laboratories
Price-to-Sales Ratio (TTM)7.423.22Bio-Rad Laboratories
Enterprise Value$4.06B$8.30BBio-Rad Laboratories
EV/Revenue Ratio7.653.25Bio-Rad Laboratories
Gross Profit Margin (TTM)61.38%52.99%TransMedics
Revenue per Share (TTM)$16$92Bio-Rad Laboratories
Earnings per Share (Diluted)$1.98$11.09Bio-Rad Laboratories
Beta (Stock Volatility)2.070.97Bio-Rad Laboratories
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

TransMedics vs Bio-Rad Laboratories Stock Performance Analysis

Loading Price Chart...

TransMedics
Bio-Rad Laboratories
TransMedics Stock Overview | Bio-Rad Laboratories Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
TransMedics-1.52%1.15%7.91%-8.98%64.76%71.32%
Bio-Rad Laboratories1.20%14.46%6.47%25.14%34.77%-5.21%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
TransMedics-15.73%191.53%742.68%359.40%359.40%359.40%
Bio-Rad Laboratories-8.24%-21.67%-44.45%123.00%239.11%455.56%

News Based Sentiment: TransMedics vs Bio-Rad Laboratories

TransMedics

News based Sentiment: POSITIVE

TransMedics experienced a month of largely positive developments, including analyst upgrades, institutional investment, and a significant partnership, offsetting a slight downward revision in Q3 revenue projections. The company's strong long-term growth trajectory and innovative technology continue to attract investor interest, making it a compelling investment story.

View TransMedics News Sentiment Analysis

Bio-Rad Laboratories

News based Sentiment: MIXED

October brought a blend of positive and negative developments for Bio-Rad Laboratories. While the stock experienced a short-term decline and a downgrade, strong institutional ownership and a positive analyst outlook suggest underlying confidence. The upcoming earnings report on October 29th will be a key catalyst for determining the company's future direction.

View Bio-Rad Laboratories News Sentiment Analysis

Performance & Financial Health Analysis: TransMedics vs Bio-Rad Laboratories

MetricTMDXBIO
Market Information
Market Cap i$4.00B$8.38B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i716,260214,510
90 Day Avg. Volume i946,893238,283
Last Close$113.93$309.17
52 Week Range$55.00 - $145.50$211.43 - $387.99
% from 52W High-21.70%-20.31%
All-Time High$177.37 (Aug 19, 2024)$832.70 (Aug 30, 2021)
% from All-Time High-35.77%-62.87%
Growth Metrics
Quarterly Revenue Growth0.38%0.02%
Quarterly Earnings Growth1.86%0.02%
Financial Health
Profit Margin (TTM) i0.13%0.13%
Operating Margin (TTM) i0.23%0.12%
Return on Equity (TTM) i0.28%0.05%
Debt to Equity (MRQ) i163.1019.73
Cash & Liquidity
Book Value per Share (MRQ)$9.35$263.42
Cash per Share (MRQ)$11.75$50.76
Operating Cash Flow (TTM) i$115.27M$534.20M
Levered Free Cash Flow (TTM) i$-7,754,500$223.40M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: TransMedics vs Bio-Rad Laboratories

MetricTMDXBIO
Price Ratios
P/E Ratio (TTM) i58.4327.55
Forward P/E i70.1226.22
PEG Ratio i0.33-0.24
Price to Sales (TTM) i7.423.22
Price to Book (MRQ) i12.381.16
Market Capitalization
Market Capitalization i$4.00B$8.38B
Enterprise Value i$4.06B$8.30B
Enterprise Value Metrics
Enterprise to Revenue i7.653.25
Enterprise to EBITDA i40.5020.23
Risk & Other Metrics
Beta i2.070.97
Book Value per Share (MRQ) i$9.35$263.42

Financial Statements Comparison: TransMedics vs Bio-Rad Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)TMDXBIO
Revenue/Sales i$157.37M$585.40M
Cost of Goods Sold i$60.78M$279.40M
Gross Profit i$96.59M$306.00M
Research & Development i$15.93M$73.50M
Operating Income (EBIT) i$36.57M$23.70M
EBITDA i$45.79M$98.50M
Pre-Tax Income i$36.18M$83.40M
Income Tax i$1.28M$19.40M
Net Income (Profit) i$34.91M$64.00M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)TMDXBIO
Cash & Equivalents i$310.14M$521.40M
Total Current Assets i$505.92M$3.04B
Total Current Liabilities i$55.60M$506.60M
Long-Term Debt i$515.62M$1.33B
Total Shareholders Equity i$266.31M$6.68B
Retained Earnings i$-442.56M$7.48B
Property, Plant & Equipment i$40.54M$681.70M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)TMDXBIO
Operating Cash Flow i$354,000$156.00M
Capital Expenditures i$-27.04M$-34.40M
Free Cash Flow i$-29.89M$95.50M
Debt Repayment iN/A$-100,000
Common Stock Repurchase iN/A$-101.90M

Short Interest & Institutional Ownership Analysis

MetricTMDXBIO
Shares Short i8.39M1.11M
Short Ratio i8.814.84
Short % of Float i0.42%0.06%
Average Daily Volume (10 Day) i716,260214,510
Average Daily Volume (90 Day) i946,893238,283
Shares Outstanding i33.62M28.01M
Float Shares i32.96M21.67M
% Held by Insiders i0.03%0.16%
% Held by Institutions i1.10%0.90%

Dividend Analysis & Yield Comparison: TransMedics vs Bio-Rad Laboratories

MetricTMDXBIO
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A